Post Herpetic Neuralgia Treatment Market
Post Herpetic Neuralgia Treatment Market Study by Drugs, Patches, and Steroid Injectables through Institutional Sales and Retail Sales from 2024 to 2034
Analysis of Post Herpetic Neuralgia Treatment Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Post Herpetic Neuralgia Treatment Market Outlook (2024 to 2034)
Fact.MR’s latest study reveals that the global post herpetic neuralgia treatment market size is forecasted to increase from a value of US$ 822.4 million in 2024 to US$ 1.38 billion by the end of 2034. This amounts to market expansion at a CAGR of 5.3% from 2024 to 2034.
Post-herpetic neuralgia (PHN) is a type of neuropathic pain triggered by an injury. Peripheral nerve damage is frequently caused by the varicella-zoster virus recurrence. The virus is the cause of shingles or herpes zoster. Neuralgia is more prevalent in areas where there is only one sensory nerve. Post-herpetic neuralgia causes pain that can last for up to 85 days. A person may have several different health issues in addition to PHN. Itching, unusual feelings, pain upon light touch, and hyperalgesia are a few examples.
Expansion of the post herpetic neuralgia treatment market size is being driven by large vendors competing for market penetration and distribution. The primary goal of the treatment for post herpetic neuralgia is symptom relief because there is no known cure for the condition.
Key Market Growth Drivers
- Development of new medications generates enormous opportunities for post herpetic neuralgia treatment providers.
- Government support and initiatives for post-herpetic neuralgia treatment worldwide are projected to bolster market growth.
- Increasing global healthcare spending is contributing to the growth of the post-herpetic neuralgia therapy market.
- Manufacturers worldwide are capitalizing on opportunities such as the growing aging population and heightened awareness of post-herpetic neuralgia treatment.
- The market is also being driven by a paradigm shift in public health awareness, supported by advancements in diagnostic tools and increased awareness of risk factors for shingles, facilitating early detection and intervention.
| Report Attributes | Details |
|---|---|
| Post Herpetic Neuralgia Treatment Market Size (2024E) | US$ 822.4 Million |
| Forecasted Market Value (2034F) | US$ 1.38 Billion |
| Global Market Growth Rate (2024 to 2034) | 5.3% CAGR |
| East Asia Market Share (2024E) | 31.1% |
| North America Market Share (2024E) | 35.2% |
| Sales of Post Herpetic Neuralgia Drugs (2024E) | US$ 668.9 Million |
| Key Companies Profiled |
|
Don't Need a Global Report?
save 40%! on Country & Region specific reports
What are the Key Post Herpetic Neuralgia Treatment Market Trends?
“Market Benefiting from Advancements in Healthcare Infrastructure Worldwide”
The market for post herpetic neuralgia treatment is projected to grow steadily due to favorable reimbursement policies and increasing awareness of the benefits of treatment. The global market is also driven by a growing geriatric population and rising prevalence of post-herpetic neuralgia. The expansion of healthcare infrastructure and government support for treatment products are projected to generate lucrative opportunities for treatment providers. Manufacturers are developing novel medications to treat post-herpetic neuralgia, setting trends in the treatment market.
“Incorporation of Digital Healthcare Technologies and Increased Accessibility to Healthcare”
Advancements in biotechnology are significantly contributing to the evolution of precision or personalized medicine, enabling more tailored treatment planning for individual patients based on their genetic composition or unique characteristics. The integration of digital health technologies, including telemedicine, mobile health apps, and remote patient monitoring, is regarded as crucial for enhancing post-herpetic neuralgia management. These innovations hold promise for improving patient outcomes, increasing healthcare accessibility, and generating valuable research data.
What are the Challenges Faced by Post Herpetic Neuralgia Treatment Providers?
“Low Efficacy of Existing PHN Treatment Drugs and Concerns about Side Effects”
The inefficacy and low efficiency of existing post-herpetic neuralgia treatment drugs are projected to hinder post herpetic neuralgia treatment market growth. Limited treatment options further obstruct market expansion. In addition, concerns regarding side effects like dizziness, drowsiness, memory impairment, increased appetite, and weight gain, along with an incomplete understanding of pathophysiology, restrain the market. The financial burden of high treatment costs also impacts patients with post-herpetic neuralgia.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Country-wise Insights
North America occupies a market share of 35% in 2024. The United States is estimated to hold 86% of the post herpetic neuralgia treatment market share in North America due to the presence of prominent players in the region. China leads the East Asia market, occupying a 50% share. South Korea holds a 30% share of the East Asia market.
How is the Post Herpetic Neuralgia Treatment Market Faring in the United States?
“Rise in PHN Screening Rates and Prevalence of Shingles among Older Adults”
| Attribute | United States |
|---|---|
| Market Value (2024E) | US$ 248 Million |
| Growth Rate (2024 to 2034) | 5.3% CAGR |
| Projected Value (2034F) | US$ 417 Million |
The United States leads the market in North America because of its increased healthcare investments to ensure seamless treatment access. The rise in screening rates for post-herpetic neuralgia treatments, coupled with the growing aging population, is driving market expansion.
- According to the Centers for Disease Control and Prevention (CDC), shingles are increasingly common among older adults in the United States. The CDC estimates that there are 4 to 5 cases of shingles per 1,000 people in the country, and 1 in 3 Americans is projected to experience shingles at some point in their lifetime.
In addition, the presence of major players like Pfizer and Endo Pharmaceuticals is contributing to the expansion of the market in the United States.
How is the Chinese Government Contributing to Market Expansion?
“Government Investments Supporting PHN Management and Prevention”
| Attribute | China |
|---|---|
| Market Value (2024E) | US$ 129 Million |
| Growth Rate (2024 to 2034) | 5.7% CAGR |
| Projected Value (2034F) | US$ 224 Million |
In major urban areas of China, post-herpetic neuralgia (PHN) imposes a significant financial burden due to both direct medical expenses and indirect costs stemming from lost productivity. It also adversely affects sleep, quality of life, and daily activities, including work performance. These expenses underscore the imperative need for effective PHN management and prevention strategies in the country.
- A study on herpes zoster and its complications in China, as reported by MDPI, revealed an incidence rate of PHN at 0.48 per 1,000 person-years. These factors collectively contribute to the growing sales of post-herpetic neuralgia treatments in China.
Category-wise Insights
The market is primarily categorized into drugs, patches, and steroid injectables, based on type. Drugs are estimated to constitute a leading share of 81% in 2024. In terms of distribution channel, the retail segment accounts for 67% market share in 2024.
Which Treatment Type is Widely Preferred by Healthcare Providers for PHN Management?
“Vital Role of Drugs in Alleviating PHN Pain”
| Attribute | Drugs |
|---|---|
| Segment Value (2024E) | US$ 668.9 Million |
| Growth Rate (2024 to 2034) | 5.4% CAGR |
| Projected Value (2034F) | US$ 1.13 Billion |
Tricyclic antidepressants (TCAs) have analgesic effects even at dosages below what is necessary for their psychological effects. These medications are affordable and essential for treating PHN. In the treatment of Parkinson's disease, gabapentin and pregabalin are first-line antiepileptic medications. They function as calcium channel blockers and aid in PHN pain relief. When it comes to managing pain after treatment, opioids are frequently chosen. They have an impact on brain chemicals that interpret pain signals in the body, like serotonin. Anticonvulsants help calm the nervous system's erratic electrical activity. They work well to reduce pain from PHN and to calm nerve impulses.
How is the Retail Segment Contributing to Increased Sales of Post Herpetic Neuralgia Products?
“Easy Accessibility and Distribution Associated with Retail Sales Channels”
| Attribute | Retail Sales |
|---|---|
| Segment Value (2024E) | US$ 553.2 Million |
| Growth Rate (2024 to 2034) | 5.6% CAGR |
| Projected Value (2034F) | US$ 951.7 Million |
PHN medications are widely accessible through various retail channels, with pharmacies, drugstores, and retail establishments conveniently located for patients. Prescription drugs like TCAs, gabapentin, and pregabalin can be easily obtained from these outlets. This accessibility is particularly convenient for patients experiencing chronic pain. This eliminates the need for patients to visit hospitals to obtain their medications.
Over-the-counter options, including certain PHN topical creams and mild pain relievers, are available in both rural and urban areas. Moreover, retail establishments conduct awareness campaigns to educate patients about PHN and available treatment resources.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Competitive Landscape
Key players in the post herpetic neuralgia treatment market are Pfizer, Arbor Pharma, Assertio Therapeutics, Endo Pharma, Teikoku Pharma, Teva, Mylan, Hengrui Medicine, Acorda Therapeutics, Purdue Pharma L.P., Teikoku Pharma USA, Inc., and Janssen Pharmaceuticals, Inc.
More than half of the revenue share of the global post herpetic neuralgia treatment market is held by Pfizer Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., and Endo Pharmaceuticals Inc.
- Acasti Pharma announced in July 2022 the commencement of the pharmacokinetic study for GTX-101, its drug candidate for postherpetic neuralgia treatment. GTX-101 is a novel formulation of bupivacaine hydrochloride (HCl) intended for topical administration via a bio-adhesive, film-forming polymer. It aims to alleviate pain associated with postherpetic neuralgia, a neuropathic pain condition resulting from nerve damage caused by the varicella-zoster virus (shingles). The application of bupivacaine hydrochloride (HCl) through the innovative GTX-101 formulation is designed to provide targeted relief when delivered topically via a bioadhesive film-forming polymer.
Segmentation of Post Herpetic Neuralgia Treatment Market Research
-
By Treatment Type :
- Drugs
- Patches
- Steroid Injectables
-
By Distribution Channel :
- Institutional Sales
- Retail Sales
-
By Region :
- North America
- Western Europe
- Eastern Europe
- Latin America
- East Asia
- South Asia & Pacific
- Middle East & Africa
Table of Content
1. Executive Summary 2. Industry Introduction 2.1. Market Taxonomy 2.2. Market Definition 3. Market Trends and Success Factors 4. Market Background 4.1. Macro-economic and Industry Outlook 4.2. Market Dynamics 4.3. Value Chain Analysis 4.4. List of Key Market Participants (Manufacturers/Channel Partners) 4.5. Analysis of Key Industry Matrices 4.6. Industry Development Roadmap 5. Global Market Demand Analysis 2019 to 2023 and Forecast 2024 to 2034 5.1. Historical Market Volume Analysis 5.2. Future Market Volume Projections 6. Pricing Analysis 7. Global Market Value (US$) Analysis 2019 to 2023 and Forecast 2024 to 2034 7.1. Historical Sales Analysis 7.2. Future Market Size and Growth Projections 8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034 by Treatment Type 8.1. Drugs 8.2. Patches 8.3. Steroid Injectables 9. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034 by Distribution Channel 9.1. Institutional Sales 9.2. Retail Sales 10. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Region 10.1. North America 10.2. Latin America 10.3. Western Europe 10.4. Eastern Europe 10.5. East Asia 10.6. South Asia and Pacific 10.7. Middle East and Africa 11. North America Sales Analysis 2019 to 2023 and Forecast 2024 to 2034 by Key Market Segments 11.1. Sales Analysis and Projections by Treatment Type 11.2. Sales Analysis and Projections by Distribution Channel 11.3. Sales Analysis and Projections for 3 Key Countries 12. Latin America Sales Analysis 2019 to 2023 and Forecast 2024 to 2034 by Key Market Segments 12.1. Sales Analysis and Projections by Treatment Type 12.2. Sales Analysis and Projections by Distribution Channel 12.3. Sales Analysis and Projections for 3 Key Countries 13. Western Europe Sales Analysis 2019 to 2023 and Forecast 2024 to 2034 by Key Market Segments 13.1. Sales Analysis and Projections by Treatment Type 13.2. Sales Analysis and Projections by Distribution Channel 13.3. Sales Analysis and Projections for 8 Key Countries 14. Eastern Europe Sales Analysis 2019 to 2023 and Forecast 2024 to 2034 by Key Market Segments 14.1. Sales Analysis and Projections by Treatment Type 14.2. Sales Analysis and Projections by Distribution Channel 14.3. Sales Analysis and Projections for 5 Key Countries 15. East Asia Sales Analysis 2019 to 2023 and Forecast 2024 to 2034 by Key Market Segments 15.1. Sales Analysis and Projections by Treatment Type 15.2. Sales Analysis and Projections by Distribution Channel 15.3. Sales Analysis and Projections for 3 Key Countries 16. South Asia & Pacific Sales Analysis 2019 to 2023 and Forecast 2024 to 2034 by Key Market Segments 16.1. Sales Analysis and Projections by Treatment Type 16.2. Sales Analysis and Projections by Distribution Channel 16.3. Sales Analysis and Projections for 4 Key Countries 17. Middle East and Africa Sales Analysis 2019 to 2023 and Forecast 2024 to 2034 by Key Market Segments 17.1. Sales Analysis and Projections by Treatment Type 17.2. Sales Analysis and Projections by Distribution Channel 17.3. Sales Analysis and Projections for 6 Key Countries 18. Sales Analysis 2024 & 2034 by Key Market Segments for 30 Countries 18.1. Sales Analysis by Treatment Type 18.2. Sales Analysis by Distribution Channel 19. Competition Outlook 19.1. Market Structure Analysis 19.2. Company Share Analysis by Key Players 19.3. Competition Dashboard 20. Company Profile 20.1. Pfizer 20.2. Arbor Pharma 20.3. Assertio Therapeutics 20.4. Endo Pharma 20.5. Teikoku Pharma 20.6. Teva 20.7. Mylan 20.8. Hengrui Medicine 20.9. Acorda Therapeutics, 20.10. Purdue Pharma L.P., 20.11. Teikoku Pharma USA, Inc., 20.12. Janssen Pharmaceuticals, Inc. 21. Assumptions and Acronyms Used 22. Research Methodology
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 01: Global Market Value (US$ Mn) Analysis, by Distribution Channel, 2019 to 2023
Table 02: Global Market Value (US$ Mn) Analysis, by Distribution Channel, 2024 to 2034
Table 03: Global Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2024 to 2034
Table 04: Global Market Value (US$ Mn) Analysis, by Treatment Type, 2019 to 2023
Table 05: Global Market Value (US$ Mn) Analysis, by Treatment Type, 2024 to 2034
Table 06: Global Market Value (US$ Mn) Opportunity Analysis, by Treatment Type, 2024 to 2034
Table 07: Global Market Value (US$ Mn) Analysis, by Region, 2019 to 2023
Table 08: Global Market Value (US$ Mn) Analysis, by Region, 2024 to 2034
Table 09: Global Market Value (US$ Mn) Opportunity Analysis, by Region, 2024 to 2034
Table 10: North America Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 11: North America Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 12: North America Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 13: North America Market Value (US$ Mn) Analysis, by Distribution Channel, 2019 to 2023
Table 14: North America Market Value (US$ Mn) Analysis, by Distribution Channel, 2024 to 2034
Table 15: North America Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2024 to 2034
Table 16: North America Market Value (US$ Mn) Analysis, by Treatment Type, 2019 to 2023
Table 17: North America Market Value (US$ Mn) Analysis, by Treatment Type, 2024 to 2034
Table 18: North America Market Value (US$ Mn) Opportunity Analysis, by Treatment Type, 2024 to 2034
Table 19: Latin America Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 20: Latin America Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 21: Latin America Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 22: Latin America Market Value (US$ Mn) Analysis, by Distribution Channel, 2019 to 2023
Table 23: Latin America Market Value (US$ Mn) Analysis, by Distribution Channel, 2024 to 2034
Table 24: Latin America Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2024 to 2034
Table 25: Latin America Market Value (US$ Mn) Analysis, by Treatment Type, 2019 to 2023
Table 26: Latin America Market Value (US$ Mn) Analysis, by Treatment Type, 2024 to 2034
Table 27: Latin America Market Value (US$ Mn) Opportunity Analysis, by Treatment Type, 2024 to 2034
Table 28: Western Europe Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 29: Western Europe Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 30: Western Europe Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 31: Western Europe Market Value (US$ Mn) Analysis, by Distribution Channel, 2019 to 2023
Table 32: Western Europe Market Value (US$ Mn) Analysis, by Distribution Channel, 2024 to 2034
Table 33: Western Europe Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2024 to 2034
Table 34: Western Europe Market Value (US$ Mn) Analysis, by Treatment Type, 2019 to 2023
Table 35: Western Europe Market Value (US$ Mn) Analysis, by Treatment Type, 2024 to 2034
Table 36: Western Europe Market Value (US$ Mn) Opportunity Analysis, by Treatment Type, 2024 to 2034
Table 37: Eastern Europe Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 38: Eastern Europe Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 39: Eastern Europe Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 40: Eastern Europe Market Value (US$ Mn) Analysis, by Distribution Channel, 2019 to 2023
Table 41: Eastern Europe Market Value (US$ Mn) Analysis, by Distribution Channel, 2024 to 2034
Table 42: Eastern Europe Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2024 to 2034
Table 43: Eastern Europe Market Value (US$ Mn) Analysis, by Treatment Type, 2019 to 2023
Table 44: Eastern Europe Market Value (US$ Mn) Analysis, by Treatment Type, 2024 to 2034
Table 45: Eastern Europe Market Value (US$ Mn) Opportunity Analysis, by Treatment Type, 2024 to 2034
Table 46: East Asia Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 47: East Asia Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 48: East Asia Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 49: East Asia Market Value (US$ Mn) Analysis, by Distribution Channel, 2019 to 2023
Table 50: East Asia Market Value (US$ Mn) Analysis, by Distribution Channel, 2024 to 2034
Table 51: East Asia Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2024 to 2034
Table 52: East Asia Market Value (US$ Mn) Analysis, by Treatment Type, 2019 to 2023
Table 53: East Asia Market Value (US$ Mn) Analysis, by Treatment Type, 2024 to 2034
Table 54: East Asia Market Value (US$ Mn) Opportunity Analysis, by Treatment Type, 2024 to 2034
Table 55: South Asia & Pacific Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 56: South Asia & Pacific Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 57: South Asia & Pacific Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 58: South Asia & Pacific Market Value (US$ Mn) Analysis, by Distribution Channel, 2019 to 2023
Table 59: South Asia & Pacific Market Value (US$ Mn) Analysis, by Distribution Channel, 2024 to 2034
Table 60: South Asia & Pacific Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2024 to 2034
Table 61: South Asia & Pacific Market Value (US$ Mn) Analysis, by Treatment Type, 2019 to 2023
Table 62: South Asia & Pacific Market Value (US$ Mn) Analysis, by Treatment Type, 2024 to 2034
Table 63: South Asia & Pacific Market Value (US$ Mn) Opportunity Analysis, by Treatment Type, 2024 to 2034
Table 64: MEA Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 65: MEA Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 66: MEA Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 67: MEA Market Value (US$ Mn) Analysis, by Distribution Channel, 2019 to 2023
Table 68: MEA Market Value (US$ Mn) Analysis, by Distribution Channel, 2024 to 2034
Table 69: MEA Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2024 to 2034
Table 70: MEA Market Value (US$ Mn) Analysis, by Treatment Type, 2019 to 2023
Table 71: MEA Market Value (US$ Mn) Analysis, by Treatment Type, 2024 to 2034
Table 72: MEA Market Value (US$ Mn) Opportunity Analysis, by Treatment Type, 2024 to 2034
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Figure 01: Global Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 02: Global Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 03: Global Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 04: Global Market Incremental $ Opportunity, 2024 to 2034
Figure 05: Global Market Share and BPS Analysis by Distribution Channel, 2024 & 2034
Figure 06: Global Market Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034
Figure 07: Global Market Attractiveness Analysis by Distribution Channel, 2024 to 2034
Figure 08: Global Market Share and BPS Analysis by Treatment Type, 2024 & 2034
Figure 09: Global Market Y-o-Y Growth Projections by Treatment Type, 2024 to 2034
Figure 10: Global Market Attractiveness Analysis by Treatment Type, 2024 to 2034
Figure 11: Global Market Share and BPS Analysis by Region, 2024 & 2034
Figure 12: Global Market Y-o-Y Growth Projections by Region, 2024 to 2034
Figure 13: Global Market Attractiveness Analysis by Region, 2024 to 2034
Figure 14: North America Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 15: North America Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 16: North America Market Value Y-o-Y Growth and Forecast, 2034
Figure 17: North America Market Incremental $ Opportunity, 2024 to 2034
Figure 18: North America Market Share Analysis by Country, 2024 & 2034
Figure 19: North America Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 20: North America Market Attractiveness Analysis by Country, 2024 to 2034
Figure 21: North America Market Share and BPS Analysis by Distribution Channel, 2024 & 2034
Figure 22: North America Market Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034
Figure 23: North America Market Attractiveness Analysis by Distribution Channel, 2024 to 2034
Figure 24: North America Market Share and BPS Analysis by Treatment Type, 2024 & 2034
Figure 25: North America Market Y-o-Y Growth Projections by Treatment Type, 2024 to 2034
Figure 26: North America Market Attractiveness Analysis by Treatment Type, 2024 to 2034
Figure 27: Latin America Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 28: Latin America Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 29: Latin America Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 30: Latin America Market Incremental $ Opportunity, 2024 to 2034
Figure 31: Latin America Market Share Analysis by Country, 2024 & 2034
Figure 32: Latin America Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 33: Latin America Market Attractiveness Analysis by Country, 2024 to 2034
Figure 34: Latin America Market Share and BPS Analysis by Distribution Channel, 2024 & 2034
Figure 35: Latin America Market Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034
Figure 36: Latin America Market Attractiveness Analysis by Distribution Channel, 2024 to 2034
Figure 37: Latin America Market Share and BPS Analysis by Treatment Type, 2024 & 2034
Figure 38: Latin America Market Y-o-Y Growth Projections by Treatment Type, 2024 to 2034
Figure 39: Latin America Market Attractiveness Analysis by Treatment Type, 2024 to 2034
Figure 40: Western Europe Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 41: Western Europe Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 42: Western Europe Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 43: Western Europe Market Incremental $ Opportunity, 2024 to 2034
Figure 44: Western Europe Market Share Analysis by Country, 2024 & 2034
Figure 45: Western Europe Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 46: Western Europe Market Attractiveness Analysis by Country, 2024 to 2034
Figure 47: Western Europe Market Share and BPS Analysis by Distribution Channel, 2024 & 2034
Figure 48: Western Europe Market Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034
Figure 49: Western Europe Market Attractiveness Analysis by Distribution Channel, 2024 to 2034
Figure 50: Western Europe Market Share and BPS Analysis by Treatment Type, 2024 & 2034
Figure 51: Western Europe Market Y-o-Y Growth Projections by Treatment Type, 2024 to 2034
Figure 52: Western Europe Market Attractiveness Analysis by Treatment Type, 2024 to 2034
Figure 53: Eastern Europe Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 54: Eastern Europe Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 55: Eastern Europe Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 56: Eastern Europe Market Incremental $ Opportunity, 2024 to 2034
Figure 57: Eastern Europe Market Share Analysis by Country, 2024 & 2034
Figure 58: Eastern Europe Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 59: Eastern Europe Market Attractiveness Analysis by Country, 2024 to 2034
Figure 60: Eastern Europe Market Share and BPS Analysis by Distribution Channel, 2024 & 2034
Figure 61: Eastern Europe Market Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034
Figure 62: Eastern Europe Market Attractiveness Analysis by Distribution Channel, 2024 to 2034
Figure 63: Eastern Europe Market Share and BPS Analysis by Treatment Type, 2024 & 2034
Figure 64: Eastern Europe Market Y-o-Y Growth Projections by Treatment Type, 2024 to 2034
Figure 65: Eastern Europe Market Attractiveness Analysis by Treatment Type, 2024 to 2034
Figure 66: East Asia Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 67: East Asia Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 68: East Asia Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 69: East Asia Market Incremental $ Opportunity, 2024 to 2034
Figure 70: East Asia Market Share Analysis by Country, 2024 & 2034
Figure 71: East Asia Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 72: East Asia Market Attractiveness Analysis by Country, 2024 to 2034
Figure 73: East Asia Market Share and BPS Analysis by Distribution Channel, 2024 & 2034
Figure 74: East Asia Market Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034
Figure 75: East Asia Market Attractiveness Analysis by Distribution Channel, 2024 to 2034
Figure 76: East Asia Market Share and BPS Analysis by Treatment Type, 2024 & 2034
Figure 77: East Asia Market Y-o-Y Growth Projections by Treatment Type, 2024 to 2034
Figure 78: East Asia Market Attractiveness Analysis by Treatment Type, 2024 to 2034
Figure 79: South Asia & Pacific Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 80: South Asia & Pacific Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 81: South Asia & Pacific Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 82: South Asia & Pacific Market Incremental $ Opportunity, 2024 to 2034
Figure 83: South Asia & Pacific Market Share Analysis by Country, 2024 & 2034
Figure 84: South Asia & Pacific Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 85: South Asia & Pacific Market Attractiveness Analysis by Country, 2024 to 2034
Figure 86: South Asia & Pacific Market Share and BPS Analysis by Distribution Channel, 2024 & 2034
Figure 87: South Asia & Pacific Market Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034
Figure 88: South Asia & Pacific Market Attractiveness Analysis by Distribution Channel, 2024 to 2034
Figure 89: South Asia & Pacific Market Share and BPS Analysis by Treatment Type, 2024 & 2034
Figure 90: South Asia & Pacific Market Y-o-Y Growth Projections by Treatment Type, 2024 to 2034
Figure 91: South Asia & Pacific Market Attractiveness Analysis by Treatment Type, 2024 to 2034
Figure 92: MEA Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 93: MEA Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 94: MEA Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 95: MEA Market Incremental $ Opportunity, 2024 to 2034
Figure 96: MEA Market Share Analysis by Country, 2024 & 2034
Figure 97: MEA Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 98: MEA Market Attractiveness Analysis by Country, 2024 to 2034
Figure 99: MEA Market Share and BPS Analysis by Distribution Channel, 2024 & 2034
Figure 100: MEA Market Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034
Figure 101: MEA Market Attractiveness Analysis by Distribution Channel, 2024 to 2034
Figure 102: MEA Market Share and BPS Analysis by Treatment Type, 2024 & 2034
Figure 103: MEA Market Y-o-Y Growth Projections by Treatment Type, 2024 to 2034
Figure 104: MEA Market Attractiveness Analysis by Treatment Type, 2024 to 2034
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
What is the estimated market size for post herpetic neuralgia treatment in 2024?
The global post herpetic neuralgia treatment market is estimated at 822.4 million in 2024.
What are the projections for the global market for the decade?
The market is forecasted to expand at 5.3% CAGR and reach US$ 1.38 billion by 2034.
What is the forecasted market size for the United States?
Revenue from post herpetic neuralgia treatment in the U.S. is forecasted to reach US$ 248 million in 2024.
What is the valuation of the market in China?
China is estimated to reach a market value of US$ 129 million in 2024.
Which type of treatment accounts for a key share in this market?
Drugs account for 81.3% market share in sales of post herpetic neuralgia treatment.
How is the PHN market faring in Japan?
Japan is projected to reach a market value of US$ 43 million in 2024.
Which distribution channel holds a significant market share?
Retail sales are estimated to account for a market value of US$ 553.2 million in 2024.
Post Herpetic Neuralgia Treatment Market